Abstract:Human MutT homolog 1 (MTH1) hydrolyses oxidised nucleotide triphosphates, thereby preventing them from being incorporated into DNA; MTH1 has been found to be elevated in many types of cancers, including lung, stomach cancer, melanoma and breast cancer. Thus, tumour-targeted hMTH1 may be valuable for developing novel anticancer therapies. In the present study, we prepared human MTH1 protein and its monoclonal antibody (mAb). The hMTH1 gene was cloned into the prokaryotic expression vector pET28a and optimally expressed in the E. coli Transetta (DE3) strain. Using an Ni-NTA column and a G-50 gel filtration column, 20.1 mg of active hMTH1 was obtained from 1,000 ml of bacterial culture, and the purity was over 98%, as detected by high-performance liquid chromatography (HPLC). The half maximal inhibitory concentration (IC50) of TH287 (hMTH1 inhibitor) was determined to be 3.53 +/- 0.47 nM using the recombinant hMTH1 protein (rhMTH1). The enzyme activity assay showed the Michaelis constant (K-m) and the catalytic constant (k(cat)) of the protein were 106.13 +/- 48.83 mu M and 3.64 +/- 0.58 sec(-1), respectively. The anti-hMTH1 mAb was obtained via the hybridoma technique and validated by western blot analysis. In addition, an immunofluorescence assay (IFA) and ELISA determined that the mAb could efficiently bind to natural hMTH1 expressed on the human breast cancer cell line MCF-7. Taken together, the results showed the rhMTH1 is an active protein and has practical applications for inhibitor selection, and our prepared hMTH1 mAb will provide a valuable tool for the further characterisation of hMTH1 and antitumour medicinal development in future.

Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity

Combined Multi-Pharmacophore, Molecular Docking and Molecular Dynamic Study for Discovery of Promising MTH1 Inhibitors

Exploration of Novel MTH1 Inhibitors Using Fragment-Based De Novo Design, Virtual Screening, and Reverse Virtual Screening Methods

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Development of MTH1-Binding Nucleotide Analogs Based on 7,8-Dihalogenated 7-Deaza-dG Derivatives

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors Through Docking-Based Virtual Screening.

Understanding the Molecular Mechanism for the Differential Inhibitory Activities of Compounds Against MTH1

Biological Characterisation and Application of Human MTH1 and Monoclonal Antibody Preparation

Potent and Specific MTH1 Inhibitors Targeting Gastric Cancer

Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA−24 with Tumor-Selective Toxicity

Targeting Human MutT Homolog 1（MTH1） for Cancer Eradication:Current Progress and Perspectives

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option

Investigation of MTH1 Activity Via Mismatch-Based DNA Chain Elongation.

Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability

Discovery and Characterization of Novel Small-Molecule Inhibitors Targeting Nicotinamide Phosphoribosyltransferase

Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L

Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-D]pyrimidine Scaffold.

Insight into the Selective Binding Mechanism of DNMT1 and DNMT3A Inhibitors: a Molecular Simulation Study.

Correction to "Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction".

Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors as Novel Anticancer Agents